Astellas Looks Up In 2010; Eisai Draws Growth From Domestic And Chinese Markets: Japanese Pharma Earnings Roundup (Part 1 Of 2)
This article was originally published in PharmAsia News
Executive Summary
Major Japanese pharmas face many of the same problems as major Western pharmas, including patent cliffs and growth slowdown in traditional markets. Japanese pharmas, on the other hand, have been slower to establish themselves in emerging markets. But that may soon be changing, as can be seen in this Japanese pharma earnings roundup, a periodic feature in PharmAsia News.
You may also be interested in...
Eisai Rides High On Expanded Oncology Capabilities, Enters Neglected Disease Foray
TOKYO - Two days after gaining U.S. FDA approval for its first in-house produced oncology product, Eisai continued its week of "firsts" with the announcement that it is the first Japanese pharmaceutical company to reach a supply agreement with the World Health Organization to combat a neglected tropical disease
Eisai Rides High On Expanded Oncology Capabilities, Enters Neglected Disease Foray
TOKYO - Two days after gaining U.S. FDA approval for its first in-house produced oncology product, Eisai continued its week of "firsts" with the announcement that it is the first Japanese pharmaceutical company to reach a supply agreement with the World Health Organization to combat a neglected tropical disease
Astellas Completes OSI Acquisition; Shares Jump In Tokyo
Astellas announced the completion of its acquisition of OSI Pharmaceuticals, obtaining 93 percent of OSI Pharmaceuticals' publicly traded shares. The New York-based company immediately became a wholly owned subsidiary of Astellas U.S. Holding